• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention refers to an individual antibiotic substance selected from the group consisting of Teichomycin A2 factor 1, Teichomycin A2 factor 2, Teichomycin A2 factor 3, Teichomycin A2 factor 4 and Teichomycin A2 factor 5 in substantially pure form, and to the method of producing them by recovery from Teichomycin A2, a known antibiotic substance, by means of high-efficiency chromatographic methods. The single pure Teichomycin A2 factor 1, Teichomycin A2 factor 2, Teichomycin A2 factor 3, Teichomycin A2 factor 4 and Teichomycin A2 factor 5 are biologically distinguishable from Teichomycin A2 in that they have a higher degree of antibiotic activity against susceptible microorganisms.
    公开号:SU1318170A3
    申请号:SU833604953
    申请日:1983-06-07
    公开日:1987-06-15
    发明作者:Борги Анджело；Палланца Роза；Коронелли Каролина；Кассани Джованни
    申请人:Группо Лепетит С.П.А. (Фирма)；
    IPC主号:
    专利说明:

    one
    This invention relates to biotology, in particular to the production of antibiotics.
    The aim of the invention is to create a method for obtaining new antibiotics - factors 1,2,3,4,5 teyhomizi on A and their salts.
    Example 1. South of teichomycin A, obtained by cultivating the strain Actinoplanes teichomyceti, cus nov. sp. ATCC 31121, dissolved in 1 liter of a 0.2% mixture of ammonium formate and acetonitrile (9: 1). The value of the RN of the resulting solution with
    1N sodium hydroxide solution is adjusted to 7.5. The solution is passed through a column containing 500 g of silica gel 60 from Merck
    Then the column is zoned with the help of a linear gradient of 10–20% acetonitrile in a 0.2% solution of ammonium formate with a total volume of 10 liters.
    Fractions (about 20 ml) are collected and examined using BTX (high pressure thin layer chromatography): column: 5 µ Lorbax® ODS (Dupont (DU Pont); mobile phase: linear gradient 0-50% solution B in A for 40 minutes, solution A: 25 mM NaH, jP04 / acetonitrile (9: 1), buffered to pH 6.0 with 0.1N NaOH; solution B; 25 mM Nall PO / acetonitrile (3: 7), buffered to pH 6.0 with 0.1 N. NaOH); flow rate
    2ml / min; detector: UV photometer at 254 nm,.
    In tab. 1 shows the retention times tg for factors 1, 2, 3, 4 and 5 of teihomycin A in an exemplary separation process using BTX, indicating in it the condition of chromatography, IT a b l and c

    0
    0 5
    0
    five
    0
    five
    Fractions with a similar BTX profile are collected and the organic solvent is evaporated under reduced pressure. The remaining aqueous solutions are passed through a column containing 10 g of graded silica gel 60 from Merck. The column is then washed with distilled water to remove ammonium formate and is spiked with 50% aqueous acetonitrile. The eluate is concentrated to a small volume by the addition of butanol to facilitate evaporation of water and precipitated with a mixture of acetone and diethyl ether (1: 1). Get 410 mg of factor
    1 and 770 mg of factor 2 teihomycin A in pure form.
    A mixture of factors 3 and 2 of Teihomycin A- (1: 1) is further purified by BTX on a semi-preparative column under the following conditions: column: Whatman Partisil® ODS M 9 10/50 (containing octadecylsilane); mobile phase: 0, -2% ammonium formate in the mixture and acetonitrile (7 6:24); flow rate: 4.5 ml / min; detector: UV photometer at 254 nm; loading: 20 mg.
    Purification is checked by examining each fraction with BTX.
    Pure factor fractions
    2 and 3 Teihomitsin A., collect, desalted and precipitated as described.
    Output: 510 mg of factor 2 and 520 mg of factor 3.
    The fractions containing factors 4 and 5 in a 1: 1 ratio (about 500 mg), obtained from the first column, are combined with another mixture of fractions containing factors 4 and 5 (about 490 mg) and obtained as a result of the second partial separation process by semi-preparative BTH, separated under the conditions described for purification of factor 3 with Teihomycin AJ, to obtain 350 mg of factor 4 and 300 mg of factor 5. I
    Factor I of teyhomycin A is a white amorphous powder, which begins to darken at about 220 ° C and completely decomposes at 255 ° C. Its chemical and physical characteristics are as follows:
    a) it is easily soluble in water at a pH of Bbmie of 7.0 or below 2, also in DMF, DMSO and propylene glycol, it is soluble in methyl cellosolve and glycerin, soluble in methanol and ethanol, and almost insoluble in chlorine
    reform, benzene, n-hexane, acetonitrile, diethylether, acetone, ethyl acetate, carbon tetrachloride;
    b) has a UV absorption spectrum of co. the following absorption maxima: 0.1 n, hydrochloric acid
      ™ I IM phosphate buffer at pH 7.4 by 278 im (, 0), in 0.1 n. sodium hydroxide L, (. 297 nm (72, 1)
    c) has an infrared absorption spectrum in nujol with the following absorption maxima: 3700-3100, 2960-2840 (nu-ol), 1645, 1590, 1510, 1460 (nu-ol), 1375 (nujol) 1305, 1230, 1180 1155 , 1060, 1025, 970, 890, 845, 815, 720 (nujol);
    d) an elementary analysis of a sample previously dried at a temperature of about 140 ° C in an inert atmosphere (%, 5) shows the following approximate average percentage composition,%: C 56.70, - H 4.90,
    N 6.65, C1 3.80, O (calculated as residue to 100%) 27.95;
    e) the retention time (t) is 21.2 min in the case of analysis by reverse phase BTX using a 5 µ Lorbax® CDS column and eluted with a linear gradient, O is 50% solution B in solution A in 40 min at a flow rate of 2 MP / min (internal standard: 3,5-dioxytoluene at t
    8.84 .min);
    e) in DMSO-d, with the addition of a few drops with a concentration of 25 mg / 0.5 ml of TMS as an internal standard:, 00 h, per million receive the following groups of signals in the 5 HR spectrum of 270 MHz H: 0.8– 1.5 (m) 1.7-2.3 (m); 2.7-4.0 (m.); 4.04, 7 (m.); 4.8-5.8 (m.); 6.2-8.1 (m.)
    g) has an acid function capable of forming salts;
    h) has a salt-forming main function;
    and) the molecular mass determined by mass spectrometry using fast atomic bombardment (SAB) as the ion source is about 1875.
    Teyhomycin A Factor 2 is a white amorphous powder, which, after heating to 210 ° C, begins to darken and decomposes completely at 250 C. Its characteristic is as follows:

    0
    five .
    0
    five

    ,
    five
    0
    704
    a) it is easily soluble in water with a pH value above 7.0 or below 2, as well as in DMF, DMSO and propylene glycol, slightly soluble in methyl cellosolve and glycerin, slightly soluble in methanol and ethanol and almost insoluble in chloroform, benzene, n hexane, acetonitrile, diethyl ether, acetone, ethyl acetate, carbon tetrachloride,
    b) has a UV absorption spectrum with the following absorption maxima:
    in 0.1 n. hydrochloric acid L „„ ,, 278 nm (E,),
    in phosphate buffer at pH 7.4, with 278 nm (E | ° 49.0);
    in 0.1 n. sodium hydroxide sodium 297 nm (K ,, 0);
    c) has a G-absorption spectrum in a nujol with the following absorption maxima: 3700-3100, 2960-2860 (nujol), 1645, 1590, 1510, 1460 (nujol), 1375 (nujol), 1300, 1260, 1230, 1180, 1150 , 1060, 1025, 970, 890, 845, 815, 720 (nujol);
    d) an elementary analysis of a sample, previously dried at a temperature of about 140 ° C in an inert atmosphere (%, 8), shows the following approximate average percentage composition,%: C 56.15; H 5.15;
    N 6.30; C1 3.90, O (calculated as residue to 100%) 28.50;
    e) retention time (t) in case of analysis by reverse phase BTX
    using a 5 micron LorSy bx CDS column and elution with
    a linear gradient of a 0-50% solution of B in solution A over 40 minutes is 22.6 minutes with a flow rate of 2 ml / min (internal standard: 3,5-dioxytoluene, tg 8.84 min);
    e) in DMSO-d with the addition of a few drops of DjO with a concentration of 25 mg / 0.5 ml (TMS as an internal standard: 0.00 ppm receive the following groups of signals
    in the NMR spectrum of 270 MHz H: 0.7-1.5 (m); 1.8-2.2 (m.); 2.7-4.5 (m.); 4.6-5.7 (m.); 6.2-8.1 (m.);
    g) has an acid function capable of forming salts;
    h) has a salt-forming main function;
    i) the molecular weight determined by mass spectrometry of the SAB is about 1877. j
    Teyhomycin A Factor 3 is a white amorphous powder which, after heating to 205 ° C
    five
    begins to decompose with complete decomposition at 250 ° C. It has the following characteristic:
    a) easily soluble in water at a pH above 7.0 or below 2, as well as in DMF, DMSO and nronylene glycol, poorly soluble in methyl cellosolve and glycerin, poorly soluble in methanol and ethanol, and almost insoluble in chloroform, benzene, n- Heck, San, Acetonitrile, Diethyl ether, Acetone, Ethyl acetate, Carbon tetrachloride.
    b) has a UV absorption spectrum with the following absorption maxima:
    in 0.1 N, hydrochloride purity slot, 278 nm (E 49, 2), in phosphate buffer at pH 7.4
     h
    Max
    278 nm (50.8), 0.1 n.
    . -. 0 {
    sodium hydroxide A mahe 297 nm (E 72.7);
    c) has an infrared absorption spectrum in a hole with the following absorption maxima: 3700-3100, 2960-2850 (nu-ol), 1645, 1590, 1510, 1460 (nu-yol), 1375 (nujol), 1300, .1230, 1180, 1150, 1120, 1060, 1030, 970,
    890, 845, 820, 800, 720 (Nujol);
    d) an elementary analysis of a sample previously dried at a temperature of about 140 ° C in an inert atmosphere (, 0) shows the following approximate average percentage composition,%: C 56.26; H 5.20; N 6.69;
    C1 3.95, O (calculated as residue to 100%) 27.90;
    e) retention time (t): in the case of analysis by reverse phase BTX using a column of 5 µ Lorbax®ODS and by elution with an χ linear gradient O - 50% solution B in solution A for 40 min em 23.3 min with a flow rate of 2 ml / min (internal standard:
    3,5-dioxytoluene at t. 8.84 min);
    e) in DMSO-dg with the addition of a few drops of Dj, 0 with concentration
    25 mg / 0.5 MP (TMS as an internal standard, 00 hours per million) receive the following groups of signals in the NMR spectrum of 270 MHz H: 0.7-1.5 (m); 1.8-2.0 (m); 2.7-4.5- (ml;
    4.6-5.7 (m.); 6.2-8.0 (m.); I
    g) has an acid function capable of forming salts;
    h) has a salt-forming main function;
    and) the molecular weight, determined by mass spectrometry of the SAB, is about 1877.
    70 6
    Teyhomycin A, j factor 4 is a white amorphous powder which, after heating to a temperature of about 210 ° C, begins to darken and decomposes completely at 250 seconds. It has the following characteristic:
    a) easily soluble in water with a pH value above 7.0 or below 2, as well as in DMF, DMSO and propylene glycol, slightly soluble in methyl cellosolve and glycerol. slightly soluble in methanol and ethanol and almost insoluble in chloroform, benzene, p-hexane, ace - tonitrile, diethyl ether, acetone, ethyl acetate, carbon tetrachloride;
    b) has a UV absorption spectrum with the following absorption maxima:
    in 0.1 n. hydrochloric acid L.ax. 278 nm (, 5),
    in phosphate buffer at pH 7.4 „, with 278 nm (, 5),
    0.1 n, sodium hydroxide Adlac 297 nm (E ;;; 75.5);
    c) has an infrared-absorption spectrum in nujol with the following absorption maxima: 3700-3100, 2960-2840 (nujol); 1645, 1590, 1510, 1460 (Nujol), 1375 (Nujol), 1300, 1230 ,. .1175, 1140, 1060, 1025, 970, 890,
    840, 815, 720 (nujol);
    d) elementary analysis of the sample. Pre-dried at a temperature of about 140 ° C in an inert atmosphere (%, j8) 5 shows the following approximate average percentage composition,%: C 56.50; H 5510;
    N 6.50; C1 is 3.80; O (calculated as residue to 100%) 28.10;
    e) the retention time (t) in the case of analysis by reverse phase BTX using a column of 5 µ Lorbax CDS and elution with a linear gradient of O - 50% solution B in solution A for 40 m is 25.8 minutes flow rate of 2 ml / min (internal standard:
    3.5-dioxy-toluene, t ,, -8.84 min);
    e) has an acid function capable of salification;
    g) has a salt-forming main function;
    h) the molecular mass determined by GAB mass spectrometry is about 1891,
    Teyhomycin A. Factor 5 is a white, amorphous powder, which, after heating to 210 ° C, begins to darken and completely decomposes.
    is at. It has the following characteristic:
    a) readily soluble in water with a pH above 7.0 or below 2, as well as in DMF, DMSO and propylene glycol, slightly soluble in methyl cellosolve and glycerin, slightly soluble in methanol and ethanol, and almost insoluble in chloroform, -benzene, p- hexane, acetonitrile, diethyl ether, acetone, ethyl acetate, and carbon tetrachloride;
    b) has a UV absorption spectrum with the following absorption maxima:
    in 0.1 n. hydrochloric acid ° te „278 nm (, 6),
    at . fossate buffer at pH 7.4 Hmax max 278 nm (, 8),
    in 0.1 n. sodium hydroxide, d, d 297 nm (, 8);
    c) has a G-absorption spectrum in-Nuol with the following absorption maxima: 3700-3100, 2960-2840 (Nu-yol), 1645, 1590, 1510, 1460 (Nu-yol), 1375 (Nujol), 1300, 1230, 1175, 1145, 1060, 1025, 970, 890, 840, 815, 720 (nujol);
    g) elementary analysis of the sample, pre-dried at a temperature of about 140 ° C in an inert atmosphere (%, l), shows the following approximate average percentage composition,%: C 56.60-, H 5.05,
    N 6.63, C1 3.85, O (calculated as residue to 100%) 27.87;
    e) the retention time (t) in the case of analysis by reverse phase BTX using a 5 µ Lorbax® ODS column and elution with a linear gradient of 0-50% solution B in solution A for 40 minutes is 26.4 minutes with a flow rate of 2 ml / min (internal standard: 3,5-dioxytoluene at t 8.84 min);
    e) has an acid function capable of forming salts;
    g) has a salt-forming main function;
     and h) the molecular weight determined by mass spectrometry of the SAB is about 1891.
    Each of the factors 1–5 of Tehomycin A2 contains an acidic residue capable of forming salts.
    PRI mme R 2. The allocation of factors 1-5 of Teihomycin A, using a chromatographic column from diethylaminoethyl sefazel.
    500 ml of DEAE-Sephacel (Farmacia Fine Chemicaks, Sweden) is poured into
    08
    column 4 cm in diameter and then equilibrated using 50 mmol ammonium chloride buffer at pH 9.0. This column is chromatographed.
    1 g of Teihomycin A complex, dissolved in 50 ml of the same buffer, was eluted with a thin mixture of the same buffer, with a linear gradient of 0-1 mol of sodium chloride in a total amount of 5 liters. Then about 20 ml fractions are collected, treated with high pressure liquid chromatography, separate fractions containing antibiotics,
    Combined and processed for the purpose of isolating substances - antibiotics.
    Below are the highest concentrations of individual factors, ml. eluted volume:
    Tehomitsinovy highest concentrate 25
    thirty
    PRI me R 3. Obtaining salts of factors 1-5.
    Salts with alkali and alkaline earth metals include sodium, potassium, lithium, calcium and magnesium salts. Ammonium salts include ammonium salts and primary, secondary, or tertiary alkyl ammonium salts C, 4, and hydroxyalkylammonium C
    Salts with alkaline and alkaline earth metals are prepared by known methods. So, factors of teykhomycin
    In the free acid form, it is dissolved in propylene glycol, followed by the gradual addition to the resulting solution of the stoichiometric amount of the selected mineral
    base, precipitation and filtration. These salts can also be obtained practically in an anhydrous form by lyophilization. In this case, aqueous solutions of the salt obtained
    as a result of the formation of salts of free acids with the help of carbonates or hydroxides of alkali or alkaline earth metals in quantities that provide the pH value in
    9131
    at limits of 7-8, filtered from insoluble substances and lyophilized,
    Organic ammonium salts are added by adding an amine to a solution of 1-5 teihomycin A actors, in free acid form, for example, in propylene glycol, followed by evaporation of the solvent and excess amine reagent or by reacting two reagents in a minimum amount of water, followed by sedimentation of the resulting salts by adding a non-solvent.
    Factors 1-5 of teyhomycin A soderate also have a hydroxide residue, due to which salts can also be formed by reacting individual factors E in their pure form with a strong acid, preferably an inertial one.
    Example 0.5 g of factor 1, 2, 3, 4, or 5 teichomycin A as free acid is dissolved in water (about 50 ml), pH 7.5. The solution is adjusted to pH 6.5 with 10% hydrochloric acid and a stoichiometric amount (or Cu8C)), dissolved in a minimum amount of water, is added.
    The mixture is stirred at room temperature to facilitate the formation of precipitates and which are collected by filtration, washed twice with acetone (about 600 ml) and dried overnight under vacuum at room temperature.
    Obtain 0.43 g (85-88%) of zinc or copper salt factor 1,2,354 or 5 teihomycin A.
    Example 5. 0.5 g of factor I, 2,3,4-OR 5 teichomycin A as a free acid is dissolved in a minimum amount of acetonitrile ... Water is added (about 50 ml), pH 7.5. Bring the solution to approximately pH 6.5 with 10% hydrochloric acid. A stoichiometric amount of BaClj (or CaCl or MgCl) dissolved in a minimum amount of water is added.
    The mixture is stirred at room temperature. The salt obtained is removed by adding an excess of acetone (about 500 ml) and filtering the resulting precipitates, which are washed twice with acetone (about 600 ml) and subjected to drying overnight in vacuum at room temperature,
    0.40 g (84-87%) of barium (calcium or magnesium) aoli is crawled.
    7010
    Example 0.5 g of factor 1.2,
    3.4 or 5 teichomycin A in the form of the free acid is dissolved in a minimum amount of acetonitrile. Water (about 50 ml), pH 7.5, is then added. The solution is brought to about pH
    6.510% hydrochloric acid. A stoichiometric amount of base is added (in the form of a concentrated water solution for
    KOH or or as a pure solution in the case of NK, jCK, NH,
    five
    N (C ,, 1,),
    ,,,, Ш (., N (CH,),,
    0
    five
    0
    five
    0
    five
    0
    five
    NH (CH,).
    etc.).
    The mixture is stirred at room temperature. The resulting salt is removed by adding an excess of acetone (about 500 ml) and filtering the resulting precipitates, which are washed twice with acetone (about 600 ml) and dried overnight in vacuo at room temperature.
    0.45 g (84-90%) of the corresponding salt is obtained.
    Primer p 7, Preparation of sodium salt of factor 2 teihomycin A.
    An aqueous solution of factor 2 teihomitsin A (150 mg, 15 ml) by adding dropwise 0.1 n. NaOH solution is adjusted to pH 8.0. The resulting solution is filtered and transferred to the freeze-drying chamber and frozen. Upon completion of freezing, the chamber is evacuated to a pressure of 0.1 Torr and the ice is sublimated by bringing the heating plate to 0 ° C, continuing this process until the product reaches an almost dry state (to a moisture content of about 1%). Titration of the sodium salt solution 2 tekhokitsin A in 25 ml methylcellosolve / (3: 1) with 0.1 g. HCl shows the presence of two titratable functions, differing in the following pH values: 7.03 and 4.78.
    According to this method, the corresponding sodium salts of factors 1, 3, 4, and 5 of teihomycin A are obtained. The determination of the amount of sodium in the final salts confirms the formation of the monosodium salt.
    The in vitro bacteriostatic activity of factors 1-5 of teihomycin A against gram-positive bacteria was determined on clinical isolates of the bacteria Staphylococcus and Streptococcus using a two-fold dilution method using micro,
    P1318170. 12
    the titration system, the concentration of which is considered to be the lowest among bacterial groups of bacteria, is the concentration at which Penasse and Todd-Hewitt stem is absent and visible growth after incubation in the Difco body. Grown broth cultures for 18-24 hours at 37 C. nights are diluted
    to a content of 10 million cells / ml. MI. The results obtained are given the minimum bacteriostatic concentration in the table. 2
     Table 2.
    Bakte zyostaticheskoe effect in vitro factors 1-5 of teyhomycin A
    The bacteriostatic activity of agar plates, inoculated sus-individual factors was determined by the mesenotomy of the test microorganism, by re-dilution with the aid of plates. The plates were incubated at 37 ° C in agar plates using bacteria of the strain S. aureus
    18 h and measure the diameters of the zones of inhibition.
    35
    ATCC 538 as a test microbe and a mixture of teyhomycin A as a reference. At the same time, identical amounts of individual factors 1-5 of Teihomycin A and the mixtures of the latter as a standard are dissolved in DMF at a concentration of 2000 µg / ml. The resulting Q solutions are further diluted with 0.067 mol of phosphate buffer to establish a pH of 7.4 and add
    Below are the test results:
    Factor teykhomycin And
    1841 and / mg
    21086 and / mg
    31131 and / mg
    41066 and / mg
    5954 and / mg Mixture of Teihomycin Aj 1000 and / mg Effect of factors 2, 3, 4 and 5
    1% bovine serum for obsteykhomycin A ,, was tested experimentally in the liver following concentrations: a cop with infection infected with S. pneu-2.5; 5J 10 and 20 µg / ml. Filmoniae and S. pyogenes discs. In order to compare the charcoal paper, Teikhomycin Aj mixture was disintegrated. the thieves of the sample and placed on a certain- The results obtained indicated
     distance to the surface
    agar plates, seeded with the suspension of the test microorganism, the plates are incubated at 37 ° C in a
    18 h and measure the diameters of the zones of inhibition.
    Below are the test results:
    Factor teykhomycin And
    1841 and / mg
    21086 and / mg
    31131 and / mg
    41066 and / mg
    5954 and / mg Mixture of Teihomycin Aj 1000 and / mg Effect of factors 2, 3, 4 and 5
    50
    experiments are given in table. 3
    Table 3 Bacteriostatic effect on mice

    ED ,,, (mg-kg / day) s / w
    S. pneumoniae S. pyogenes)
    0.28 (0.22-0, 34) 0.15 (0.13-0.18)
    0.27 (0.23-0.32) 0.13 (0.11-0.16)
    0.12 (0.98-0.14) 0.098 (0.073-0.11)
    0.13 (0.10-0, 15) 0.10 (0.098-0.13)
    Mixture
    Teihomitsin A, 0.35 (0.28-0.44) 0.8 (-)
    The approximate acute toxicity in mice (intraperitoneally) for factors 1-5 of Teihomycin A is given in Table. four.
    Table 4
    Acute toxicity in mice (intraperitoneally)
    Approximate LD mg / kg
    about
    1500.С2000
    1500s2000
    1000: 1500
    500 1000
    From tab. 4 it follows that factors 1-5 of teyhomycin A are suitable for use as an active principle in antimicrobial preparations in medicine and veterinary medicine for the prevention and treatment of infectious diseases caused by pathogenic bacteria susceptible to these compounds m.-The proposed compounds can be used for the treatment of infectious diseases per se, i.e. as separate factors or because of the similarity of their activity characteristics and as a mixture of two or: more factors in any ratio.
    The compound is administered orally, topically or parenterally, preferably parenterally. Depending on the method of application of the compound
    prepared in various dosage forms. For oral administration, the preparations may be capillary, tablets, liquid solutions or suspensions. As is well known, capsules and tablets, in addition to the active principle, may contain also usual inert fillers (carriers), such as
    0 diluents, such as lactose, calcium phosphate, sorbitol, etc., lubricants, such as magnesium stearate, talc, polyethylene glycol, binders, such as polyvinylpyrrolidone, gelatin,
    sorbitol, tragant, gum, flavoring substances, decomposition agents and wetting agents. Liquid preparations, usually in the form of aqueous or oily solutions or suspensions, may contain conventional additives, for example substances that assist in the weighing. For topical use, the compounds can be formulated for administration
    5 through the mucous membranes of the nose and throat or bronchial tissues, usually in the form of liquid aerosols or means for inhalation, pellets or tinctures applied to the surface of the throat. Liquid or semi-liquid preparations can be used to treat the eyes or the sting. Topical preparations can be prepared on a hydrophobic or hydrophilic basis in the form of ointments, creams, lotions, tinctures or powders, the injectable formulations can be in the form of suspensions, solutions or emulsions based on oily or aqueous carriers containing substances that promote
    0
    0
    five
    151
    weighing, stabilizers and / or dispersants. In addition, the active agent can initially be prepared as a powder for its reproduction during delivery with a suitable carrier, for example, sterile water.
    The amount of active principle employed depends on various factors, such as growth and health of the patient (animal), the method and frequency of use of the drug, and the cause of the disease. As a rule, factors 1-5 of teyhomycin A are effective at a daily dosage in the range of about 0, 1-20 mg of active principle per kg of weight, and this dose can be divided into two doses per day. Suitable formulations prepared in the form of dosage units with a content of about .50-250 mg of active ingredient per unit.
    . Examples of pharmaceutical formulations: a solution for parenteral administration of 100 mg of Teihomycin A factor 2 sodium salt dissolved in 2 ml of sterile water for injection; parenteral solution of 250 mg of Teihomycin A factor 3 sodium dissolved in 3 MP sterile water for injection; ointment for topical application of 200 mg of factor 2 teihomycin A, 600 mg of polyethylene glycol 4000 U.S.P. 1.2 g polyethylene glycol 400 U.S.P.
    Along with the use of drugs, the proposed compounds can also be used as promoters of animal growth. For this purpose, one or more compounds are administered orally.
    Editor K. Voloshchuk Order 2441/58
    Compiled by G.Smirnova Tehred M. Morgenthal
    Corrector
    Circulation 499 Subscription
    VNIISH State Committee of the USSR
    for inventions and discoveries 113035, Moscow, Zh-35, Raushsk nab., 4/5
    Production and printing company, Uzhgorod, st. Project, 4
    70
    with feed
    sixteen
    This selects such a concentration of compounds that is effective for promoting animal growth. In this case, a mixture of a part of the feed is first prepared with an effective amount of the active compounds, which is then added to the full portion of the feed, or an intermediate concentrate containing the active principle is mixed with the feed.
    权利要求:
    Claims (2)
    [1]
    1. A method of obtaining factors 1,2, 3,4,5 teihomycin A and their salts, which consists in that teiomycin obtained by cultivating the strain Actonoplanes teichomyceticus nov. sp. ATCC 31121, transferred to a solution, subjected to reverse phase chromatography on a column containing silanated silica gel, eluted using a linear gradient from 10 to 20% acetonitrile in 0.2% ammonium formate, the resulting fractions of a similar profile are combined, concentrated Target products are precipitated and / or converted to salt.
    [2]
    2. Method POP1, characterized in that, in order to further separate factors 2, 3, 4, 5 of teihomycin A, a mixture of factors 2, 3, 4 and 5 is subjected to reverse phase chromatography on a column containing octadecylsilane, eluted with a mixture of acetonitrile and 0.2% aqueous ammonium formate in a ratio of 24:76, followed by desalting of the fractions.
    and precipitation of the desired products.
    Proofreader I. Muska
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1318170A3|1987-06-15|Method for producing factors 1,2,3,4,5 of teichomycin a2 and salts thereof
    IE42067B1|1980-05-21|Antibiotic azetidinopyrrole derivative
    DE2517316A1|1975-10-23|CLAVULANIC ACID, THEIR SALTS AND ESTERS, PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
    NL192989C|1998-07-03|Antibiotic, method of preparation and pharmaceutical preparation containing this antibiotic.
    US6048977A|2000-04-11|Clavulanic acid and salts thereof
    EP0231111B1|1991-08-07|Glycopeptide antibiotics, their preparation and use and microorganisms for producing them
    US4141986A|1979-02-27|Antibiotics 890A2 and 890A5
    HU188684B|1986-05-28|Process for producing a2, and simultaneously produced a1 and a3 components of antibioticum a/16686
    HU179463B|1982-10-28|Process for preparing deoxy-narasin antibiotic complex
    US3639590A|1972-02-01|Antibacterial composition containing | | phosphoric acid
    US4623733A|1986-11-18|Antimicrobial peptide
    US5994543A|1999-11-30|Antibiotic bravomicins
    US4452782A|1984-06-05|Pentadecapeptide
    EP0468504B1|1997-10-15|A novel antibiotic, balhimycin, a process for its production and its use as pharmaceutical
    NL8001842A|1980-11-04|NEW ANTIBIOTICS CALLED ISTAMYCINES, PROCESSES FOR THE PREPARATION OF THESE ANTIBIOTICS, AND PHARMACEUTICAL PREPARATIONS WITH AN EFFECT AGAINST THESE ANTIBIOTICS AND THE PROCESS OF ITS PROPERTIES.
    EP0055299B1|1985-01-09|Antibiotic y-16482 alpha and/or antibiotic y16482 beta, process for their preparation, and medicinal composition containing the same
    US4426390A|1984-01-17|Novel β-lactam compounds, process for producing thereof, and use thereof as medicines
    DE4327226A1|1995-02-16|Chelators, their preparation from the antibiotics salmycin A, B or C and their use
    US4623722A|1986-11-18|Fortimicin factor KG3
    US4137224A|1979-01-30|Process for the preparation of antibiotic W-10 complex and for the isolation of antibiotic 20561 and antibiotic 20562 therefrom
    US4427655A|1984-01-24|Antibiotics-875A and production thereof
    EP0289354A2|1988-11-02|Antibiotic TAN-950A, its production and use
    US4264735A|1981-04-28|Method of producing antibiotic 890A9
    EP0086610A1|1983-08-24|Substance potentiating the activity of antibiotics and its production
    EP3898610A1|2021-10-27|Novel aza-hexaphene antibiotic compounds
    同族专利:
    公开号 | 公开日
    FI831660A0|1983-05-12|
    JPH0517237B2|1993-03-08|
    NO831754L|1983-12-09|
    SE459094B|1989-06-05|
    DK159117C|1991-02-11|
    FI831660L|1983-12-09|
    US4542018A|1985-09-17|
    DK245883D0|1983-05-31|
    CH657139A5|1986-08-15|
    GB2121401A|1983-12-21|
    DE3320342C2|1991-07-11|
    IE831329L|1983-12-08|
    ES8506748A1|1985-08-16|
    NL8301980A|1984-01-02|
    IT8321432D0|1983-06-02|
    NZ204480A|1986-04-11|
    JPH0224278B2|1990-05-29|
    DE3320342A1|1983-12-08|
    ES522941A0|1985-04-01|
    KR900008246B1|1990-11-06|
    HK55887A|1987-08-07|
    SG70686G|1987-07-03|
    LU84853A1|1984-03-07|
    IE55025B1|1990-04-25|
    IT1212085B|1989-11-08|
    NO159104C|1988-11-30|
    GB2121401B|1985-09-18|
    JPH0517236B2|1993-03-08|
    PT76831A|1983-07-01|
    MY8700002A|1987-12-31|
    IL68819D0|1983-09-30|
    KR840005170A|1984-11-05|
    BG60529B2|1995-07-28|
    AU1496883A|1983-12-15|
    PT76831B|1986-04-09|
    PH19533A|1986-05-20|
    UA6025A1|1994-12-29|
    CA1208204A|1986-07-22|
    JPH0415238B2|1992-03-17|
    JPH02291279A|1990-12-03|
    GB8315003D0|1983-07-06|
    JPH02291278A|1990-12-03|
    JPH02288888A|1990-11-28|
    JPS591423A|1984-01-06|
    DK245883A|1983-12-09|
    ES8503689A1|1985-04-01|
    SE8303211D0|1983-06-07|
    ZA833607B|1984-03-28|
    FI73697B|1987-07-31|
    SE8303211L|1983-12-09|
    GR78267B|1984-09-26|
    AU560966B2|1987-04-30|
    DK159117B|1990-09-03|
    FI73697C|1987-11-09|
    BE896993A|1983-12-07|
    ES536770A0|1985-08-16|
    FR2528050A1|1983-12-09|
    NO159104B|1988-08-22|
    JPH0415237B2|1992-03-17|
    JPH02288887A|1990-11-28|
    FR2528050B1|1987-03-20|
    HU193538B|1987-10-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1496386A|1975-03-05|1977-12-30|Lepetit Spa|Antibiotics|GB8307847D0|1983-03-22|1983-04-27|Lepetit Spa|Antibiotics l 17054 and l 17046|
    US4696817A|1983-10-11|1987-09-29|The Dow Chemical Company|Extraction of teichomycin A2 from whole culture fermentation broth|
    GB8333624D0|1983-12-16|1984-01-25|Lepetit Spa|Antibiotics l 17054 and l 17392|
    GB8415092D0|1984-06-13|1984-07-18|Lepetit Spa|Ester derivatives|
    GB8415093D0|1984-06-13|1984-07-18|Lepetit Spa|Antibiotic l 17392|
    GB8428619D0|1984-11-13|1984-12-19|Lepetit Spa|Derivatives of antibiotic l 17046|
    GB8512795D0|1985-05-21|1985-06-26|Lepetit Spa|Increasing ratio of components of teicoplanin a2 complex|
    US4694069A|1985-09-30|1987-09-15|Smithkline Beckman Corporation|Kibdelosporangium aridum SK&F-AAD-609|
    JPS61241319A|1986-04-25|1986-10-27|Kanegafuchi Chem Ind Co Ltd|Room temperature curing composition containing novel ether-ester block copolymer|
    US4845194A|1987-02-27|1989-07-04|Eli Lilly And Company|Glycopeptide recovery process|
    GB8715735D0|1987-07-03|1987-08-12|Lepetit Spa|De-mannosyl teicoplanin derivatives|
    US4996148A|1987-07-13|1991-02-26|Eli Lilly And Company|A80407 antibiotics|
    US5213797A|1987-07-13|1993-05-25|Eli Lilly And Company|A80407 antibiotics|
    GB8720980D0|1987-09-07|1987-10-14|Lepetit Spa|Derivatives|
    US5194424A|1988-12-27|1993-03-16|Gruppo Lepetit Spa|C63 -amide derivatives of 34-de-34-deoxy-teicoplanin and their use as medicaments against bacteria resistant to glycopeptide antibiotics|
    AT134379T|1990-12-05|1996-03-15|Lepetit Spa|38-DECARBOXY-38-HYDROXYMETHYL DERIVATIVES OF TEICOPLANINANTIBIOTICS, AND METHOD FOR THE PRODUCTION THEREOF|
    US5606036A|1991-03-27|1997-02-25|Gruppo Lepetit Spa|Antibiotic A 40926 ester derivatives|
    CA2250578C|1996-04-23|2003-06-24|Versicor Inc.|Improved chemical process for preparing amide derivatives of antibiotic a 40926|
    KR100476818B1|2002-07-19|2005-03-17|종근당바이오 주식회사|Purification method for teicoplanin A2|
    US7119061B2|2002-11-18|2006-10-10|Vicuron Pharmaceuticals, Inc.|Dalbavancin compositions for treatment of bacterial infections|
    KR20120056310A|2002-11-18|2012-06-01|비큐론 파마세티컬스 인코포레이티드|Methods of administering dalbavancin for treatment of bacterial infections|
    US20060074014A1|2002-11-18|2006-04-06|Vicuron Pharmaceuticals Inc.|Dalbavancin compositions for treatment of bacterial infections|
    EP1806150A1|2006-01-05|2007-07-11|NEED PHARMA S.r.l.|Teicoplanin composition|
    CN102718843B|2012-06-30|2014-05-14|华北制药集团新药研究开发有限责任公司|Preparation method of single teicoplanin components|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB8216590|1982-06-08|
    [返回顶部]